Agios Pharmaceuticals Inc banner

Intrinsic Value

The intrinsic value of Agios Pharmaceuticals Inc (0HB0) under the Base Case is USD per share. Compared with the current market price of 30.56 USD, the stock appears .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

0HB0 Intrinsic Value

What one share is worth in the bear, base and bull cases.

Create a free account · No card needed

Do our valuations actually work? See backtest results .

Alert me when 0HB0 is below its intrinsic value
Today Hidden ·
0HB0 Valuation History

Intrinsic value next to the price over the past 11 months.

Create a free account · No card needed

Alternatives to 0HB0

Fundamental Analysis

What Agios Pharmaceuticals Does

Biotechnology Health Care

Agios Pharmaceuticals is a biotech company that develops medicines for rare blood disorders. Its main approved drug is Pyrukynd, a pill used to treat certain inherited anemia conditions by helping red blood cells make energy more efficiently. The company also keeps working on other drug candidates in rare hematology, using the same idea of targeting cell metabolism.

Headquarters
United States of America US
Employees
539
IPO date
Jul 24, 2013
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Ownership

Agios Pharmaceuticals insiders are selling within their usual range

Insider trading · Last trade on Oct 26, 2026

Sold $3.6m 7 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Continue 0HB0 Research

Decided on Agios Pharmaceuticals? Get an email when 0HB0 reaches the price you’d buy at. Free with an account.

Other Agios Pharmaceuticals listings

What is the Intrinsic Value of one 0HB0 stock?

The intrinsic value for Agios Pharmaceuticals Inc (0HB0) under the Base Case is USD.

Is 0HB0 stock undervalued or overvalued?

Compared with the current market price of 30.56 USD, the stock appears .

How reliable are our estimates? See how past valuations played out
Back to Top